Reproductive Health

According to the World Health Organization (WHO), reproductive health is defined as a state of complete physical, emotional, behavioural, and social well-being in all aspects relating to the reproductive system, its functions, and processes. A reproductively healthy society consists of individuals possessing functionally normal reproductive organs, healthy emotional interactions, and responsible attitudes towards sexual behaviour and family planning.

India was the first nation globally to initiate a nationwide Family Planning Programme in 1951. Over successive decades, these policies broadened into the comprehensive Reproductive and Child Health Care (RCH) Programme, focusing on the following strategic objectives:

• Awareness Creation: Educating adolescents and eligible couples regarding safe sex practices, contraception, puberty changes, menstrual hygiene, and sexually transmitted infections (STIs).
• Clinical Infrastructure: Providing institutional delivery facilities, prenatal, natal, and postnatal maternal care, and comprehensive infant immunization programs.
• Reduction of Mortality Indices: Systematically bringing down the Maternal Mortality Ratio (MMR) and Infant Mortality Rate (IMR) through nutritional supplementation and emergency obstetric services.
• Population Stabilization: Promoting smaller family norms (e.g., 'Hum Do, Hamare Do') through widespread distribution of user-friendly contraceptives.

The 20th century witnessed unprecedented exponential population growth globally and nationally. India's population swelled from ~350 million at independence (1947) to over 1 billion by 2000 and continues to grow. The primary demographic drivers of this explosion are:

An ideal contraceptive must be user-friendly, easily accessible, highly effective with negligible failure rate, completely reversible with immediate return of fertility upon cessation, devoid of adverse physiological side effects, and non-interfering with the user's sexual drive or desire.

These physiological methods operate on the core principle of preventing the physical encounter between the ovum and sperm without the use of exogenous devices or chemicals. While free of side effects, their failure rates remain relatively high:

• Periodic Abstinence (Rhythm Method): Coitus is avoided during the fertile window of the menstrual cycle (typically Day 10 to Day 17 in an idealized 28-day cycle), when ovulation is most likely. Because sperm survives ~48-72 hours in the female tract and ovum lives for ~24 hours post-ovulation, abstinence during this 8-day window substantially reduces fertilization risk.
• Coitus Interruptus (Withdrawal): The male withdraws the penis from the vagina just prior to ejaculation, depositing semen externally. High failure rates occur due to pre-ejaculatory bulbourethral emissions containing viable spermatozoa.
• Lactational Amenorrhea: Based on the neuroendocrine fact that intense breastfeeding (suckling stimulus) elevates anterior pituitary Prolactin secretion. Hyperprolactinemia exerts strong negative feedback inhibition on hypothalamic GnRH pulsatility, suppressing pituitary LH and FSH release. Consequently, follicular maturation, ovulation, and menstruation are blocked. Effective strictly up to 6 months postpartum, provided breastfeeding is exclusive and unsupplemented.

Barriers physically prevent ejaculated spermatozoa from reaching the uterine cervix:

• Condoms: Thin latex/polyurethane sheaths for males (e.g., brand 'Nirodh') or females (femidoms). Highly unique as the only contraceptive modality offering dual protection against both unwanted pregnancy and Sexually Transmitted Infections (STIs, including HIV/AIDS). Non-reusable and self-administered.
• Diaphragms, Cervical Caps & Vaults: Rubber/silicone cups inserted into the female reproductive tract to cover the external os of the cervix prior to coitus. Reusable; their contraceptive efficacy is significantly boosted when paired with chemical spermicidal creams, jellies, or foams containing Nonoxynol-9.

IUDs are the most widely accepted and utilized contraceptive method in India for spacing children. Inserted strictly by trained physicians or nurse practitioners into the uterine cavity via the cervix. Classified into three distinct functional categories:

Daily oral pills containing low doses of either progestogen alone (mini-pills) or synthetic progestogen-estrogen combinations (e.g., Mala-D, Mala-N). Administration regimen:

• Ingested daily for 21 consecutive days, starting within the first 5 days of the menstrual cycle.
• Followed by a 7-day pill-free interval (during which withdrawal bleeding/menstruation occurs), often substituted with ferrous fumarate (iron) tablets.
• Triple Action Mechanism:
  1. Inhibition of ovulation via negative feedback on pituitary FSH and LH secretions (suppresses mid-cycle LH surge).
  2. Alteration of uterine endometrium to prevent blastocyst nidation (implantation).
  3. Thickening of cervical mucus to impede sperm penetrance.

Saheli is a landmark Indian indigenous oral contraceptive developed by scientists at the Central Drug Research Institute (CDRI), Lucknow. Key scientific attributes:

• Non-Steroidal Chemistry: Contains Centchroman (Ormeloxifene), a Selective Estrogen Receptor Modulator (SERM). Devoid of steroid hormones, eliminating classic steroid-induced side effects (weight gain, nausea, fluid retention, cardiovascular risks).
• Convenient Dosage: Administered twice-a-week for the initial 3 months, followed by once-a-week thereafter.
• Mechanism: Antagonizes uterine estrogen receptors, accelerating ovum transport and desynchronizing the endometrium so that it remains completely unreceptive to blastocyst implantation. Extremely high contraceptive efficacy with virtually zero systemic toxicity.

• Injectables: Intramuscular depot injections of progestogens (e.g., DMPA - Depot Medroxyprogesterone Acetate, 150 mg every 3 months). Provides prolonged protection by sustained suppression of ovulation.
• Subdermal Implants (e.g., Norplant): Six flexible silastic capsules containing levonorgestrel implanted under the subdermal skin of the upper arm. Slowly diffuses progestin over a lifespan of 3 to 5 years. Highly reversible upon minor surgical extraction.
• Emergency Contraception (Morning-After Pills): Ingestion of high-dose progestogens (e.g., 1.5 mg Levonorgestrel / i-Pill) or insertion of a Copper-T within 72 hours of unprotected coitus, condom breakage, or sexual assault. Acts acutely by arresting impending ovulation or inhibiting implantation. Strictly for emergency use, not a routine birth-control measure.

Surgical intervention blocks gamete transport, providing permanent contraception. Reversibility is extremely poor (<10-20% success rate for reanastomosis):

Medical Termination of Pregnancy (MTP) is the intentional or voluntary termination of pregnancy prior to fetal viability. Globally, nearly 45 to 50 million MTPs are performed annually (~20% of total conceived pregnancies). Key clinical and legislative facets:

• Legalization in India (MTP Act 1971): The Government of India legalized MTP in 1971 with stringent statutory riders to prevent maternal mortality caused by unsafe quack abortions and to preclude misuse for female foeticide.
• MTP Amendment Act (2021) Regulatory Framework:
  • Up to 20 Weeks: Pregnancy can be terminated on the professional opinion of one registered medical practitioner.
  • 20 to 24 Weeks: Permissible for defined vulnerable categories (survivors of rape/incest, minors, women with physical/mental disabilities, major fetal abnormalities) upon concurring opinion of two registered medical practitioners.
  • Beyond 24 Weeks: Permitted strictly for diagnosed substantial fetal structural or chromosomal abnormalities approved by a state-level four-member Medical Board.
• Safety Window: MTP is considered relatively safe during the first trimester (up to 12 weeks of gestation). Second-trimester terminations (12 to 24 weeks) are dramatically more hazardous due to vascularization of the placenta and risk of uterine rupture, massive hemorrhage, and sepsis.
• Medical Method (Non-Surgical): Administration of oral Mifepristone (RU-486), a competitive synthetic anti-progesterone antagonist that detaches the trophoblast by blocking progesterone receptors, followed 48 hours later by oral/vaginal Misoprostol (a prostaglandin E1 analogue) that induces powerful uterine contractions to expel the conceptus.

Amniocentesis is a transabdominal invasive prenatal diagnostic technique performed between the 15th and 20th weeks of gestation. Under continuous ultrasound visualization, a fine hypodermic needle is introduced through the maternal abdominal and uterine walls into the amniotic sac to aspirate ~15-20 mL of amniotic fluid containing desquamated fetal cutaneous and mucosal epithelial cells (fibroblasts).

Sexually Transmitted Infections (STIs), historically termed Venereal Diseases (VD) or Reproductive Tract Infections (RTI), are infectious diseases transmitted predominantly via sexual intercourse (vaginal, oral, or anal), as well as through contaminated blood transfusions, shared hypodermic needles, and vertical transmission from mother to fetus across the placenta or birth canal.

Untreated STIs lead to devastating long-term complications including Pelvic Inflammatory Disease (PID), Fallopian tube scarring, ectopic tubal pregnancies, recurrent spontaneous abortions, stillbirths, bilateral tubal obstruction causing permanent female infertility, and reproductive tract carcinomas.

• Primary Prevention: Abstinence from casual, unprotected intercourse and sexual activity with unknown/multiple partners.
• Universal Barrier Protection: Consistent and proper utilization of condoms during every sexual encounter.
• Early Diagnosis & Complete Therapy: Seeking immediate medical evaluation at specialized STI clinics upon detecting early warning signs (genital sores, persistent itching, fluid discharge, or pelvic pain) and ensuring both sexual partners undergo simultaneous complete antibiotic/antiviral treatment to prevent ping-pong reinfection.

Infertility is clinically defined as the biological inability of a couple to achieve clinical pregnancy despite one year (or two years as per WHO) of regular, unprotected sexual coitus. Infertility stems from male factors (~40%), female factors (~40%), combined factors (~10%), or unexplained idiopathic causes (~10%):

• Male Etiological Factors: Azoospermia (absence of sperm), Oligospermia (sperm concentration <15 million/mL), Asthenozoospermia (poor sperm motility), Teratozoospermia (abnormal morphology), cryptorchidism, testicular trauma, varicocele, and erectile dysfunction.
• Female Etiological Factors: Anovulation / Polycystic Ovarian Syndrome (PCOS), bilateral tubal obstruction or adhesion (post-salpingitis or PID), uterine fibroids/endometriosis, hostile cervical mucus, and premature ovarian insufficiency.

When specialized corrective medical or surgical treatments fail, couples are assisted through advanced biological techniques:

Gestational Surrogacy involves an arrangement where another woman (the surrogate mother) carries an in vitro fertilized embryo (created from intended parents' or donor gametes) to term and delivers the neonate for the commissioning couple. In India, the Surrogacy (Regulation) Act 2021 strictly prohibits commercial surrogacy, permitting only altruistic surrogacy for legally eligible infertile Indian couples with medical certification of uterine agenesis or recurrent pregnancy loss. Legal adoption under CARA (Central Adoption Resource Authority) remains an emotionally fulfilling and legally sanctioned alternative for childless couples.